Search Results - "BECKER, Richard C"

COVID-19-associated vasculitis and vasculopathy by Becker, Richard C.

“…The COVID-19 pandemic now totaling 13,000,000 cases and over 571,000 deaths has continued to teach the medical, scientific and lay communities about viral…”
Get full text

COVID-19 update: Covid-19-associated coagulopathy by Becker, Richard C

Get full text

Aptamers as Therapeutics by Nimjee, Shahid M, White, Rebekah R, Becker, Richard C, Sullenger, Bruce A

“…Aptamers are single-stranded nucleic acid molecules that bind to and inhibit proteins and are commonly produced by systematic evolution of ligands by…”
Get full text

Translational Implications of Platelets as Vascular First Responders by Becker, Richard C, Sexton, Travis, Smyth, Susan S

“…Platelets play a vital role in normal hemostasis to stem blood loss at sites of vascular injury by tethering and adhering to sites of injury, recruiting other…”
Get full text

Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium by Gorog, Diana A., Storey, Robert F., Gurbel, Paul A., Tantry, Udaya S., Berger, Jeffrey S., Chan, Mark Y., Duerschmied, Daniel, Smyth, Susan S., Parker, William A. E., Ajjan, Ramzi A., Vilahur, Gemma, Badimon, Lina, Berg, Jurrien M. ten, Cate, Hugo ten, Peyvandi, Flora, Wang, Taia T., Becker, Richard C.

“…Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and thromboembolic events, owing to excessive inflammation, endothelial cell activation…”
Get full text

Vascular Smooth Muscle Cells in Aortic Aneurysm: From Genetics to Mechanisms by Lu, Haocheng, Du, Wa, Ren, Lu, Hamblin, Milton H, Becker, Richard C, Chen, Y Eugene, Fan, Yanbo

“…Aortic aneurysm, including thoracic aortic aneurysm and abdominal aortic aneurysm, is the second most prevalent aortic disease following atherosclerosis,…”
Get full text

Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding by Tantry, Udaya S., PhD, Bonello, Laurent, MD, PhD, Aradi, Daniel, MD, PhD, Price, Matthew J., MD, Jeong, Young-Hoon, MD, PhD, Angiolillo, Dominick J., MD, PhD, Stone, Gregg W., MD, Curzen, Nick, BM (hons), PhD, Geisler, Tobias, MD, ten Berg, Jurrien, MD, PhD, Kirtane, Ajay, MD, SM, Siller-Matula, Jolanta, MD, PhD, Mahla, Elisabeth, MD, Becker, Richard C., MD, Bhatt, Deepak L., MD, MPH, Waksman, Ron, MD, Rao, Sunil V., MD, Alexopoulos, Dimitrios, MD, Marcucci, Rossella, MD, PhD, Reny, Jean-Luc, MD, PhD, Trenk, Dietmar, PhD, Sibbing, Dirk, MD, Gurbel, Paul A., MD

“…Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to reduce platelet reactivity and to prevent thrombotic events in…”
Get full text

Epigenetic modification: a regulatory mechanism in essential hypertension by Arif, Mohammed, Sadayappan, Sakthivel, Becker, Richard C, Martin, Lisa J, Urbina, Elaine M

“…Essential hypertension (EH) is a multifactorial disease of the cardiovascular system that is influenced by the interplay of genetic, epigenetic, and…”
Get full text

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial by Wallentin, Lars, Prof, James, Stefan, MD, Storey, Robert F, MD, Armstrong, Martin, PhD, Barratt, Bryan J, PhD, Horrow, Jay, MD, Husted, Steen, MD, Katus, Hugo, Prof, Steg, P Gabriel, Prof, Shah, Svati H, MD, Becker, Richard C, Prof

“…Summary Background In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute coronary syndromes, ticagrelor reduced the composite outcome of…”
Get full text

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer by Povsic, Thomas J., MD, PhD, Lawrence, Monica G., MD, Lincoff, A. Michael, MD, Mehran, Roxana, MD, Rusconi, Christopher P., PhD, Zelenkofske, Steven L., DO, Huang, Zhen, MS, Sailstad, Jeffrey, BS, Armstrong, Paul W., MD, Steg, P. Gabriel, MD, Bode, Christoph, MD, Becker, Richard C., MD, Alexander, John H., MD, MHS, Adkinson, N. Franklin, MD, Levinson, Arnold I., MD

“…Murine models of anaphylaxis have suggested that IgG antibody/allergen complexes interacting with Fcγ receptors on basophils and neutrophils release…”
Get full text

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study by Cannon, Christopher P, Dr, Harrington, Robert A, Prof, James, Stefan, MD, Ardissino, Diego, MD, Becker, Richard C, Prof, Emanuelsson, Håkan, MD, Husted, Steen, MD, Katus, Hugo, Prof, Keltai, Matyas, Prof, Khurmi, Nardev S, MD, Kontny, Frederic, MD, Lewis, Basil S, Prof, Steg, Philippe Gabriel, Prof, Storey, Robert F, MD, Wojdyla, Daniel, MSc, Wallentin, Lars, Prof

“…Summary Background Variation in and irreversibility of platelet inhibition with clopidogrel has led to controversy about its optimum dose and timing of…”
Get full text

Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial by Wong, Ka Sing Lawrence, Hu, Dai Yi, Oomman, Abraham, Tan, Ru-San, Patel, Manesh R, Singer, Daniel E, Breithardt, Günter, Mahaffey, Kenneth W, Becker, Richard C, Califf, Robert, Fox, Keith A.A, Berkowitz, Scott D, Hacke, Werner, Hankey, Graeme J

“…BACKGROUND AND PURPOSE—In Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial…”
Get full text

Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial by Piccini, Jonathan P., MD, MHS, Stevens, Susanna R., MS, Lokhnygina, Yuliya, PhD, Patel, Manesh R., MD, Halperin, Jonathan L., MD, Singer, Daniel E., MD, Hankey, Graeme J., MD, Hacke, Werner, MD, PhD, Becker, Richard C., MD, Nessel, Christopher C., MD, Mahaffey, Kenneth W., MD, Fox, Keith A.A., MB, ChB, Califf, Robert M., MD, Breithardt, Günter, MD

“…Objectives This study sought to investigate the outcomes following cardioversion or catheter ablation in patients with atrial fibrillation (AF) treated with…”
Get full text

Factors Associated With Major Bleeding Events by Goodman, Shaun G., MD, MSc, Wojdyla, Daniel M., MS, Piccini, Jonathan P., MD, White, Harvey D., MB, ChB, DSc, Paolini, John F., MD, PhD, Nessel, Christopher C., MD, Berkowitz, Scott D., MD, Mahaffey, Kenneth W., MD, Patel, Manesh R., MD, Sherwood, Matthew W., MD, Becker, Richard C., MD, Halperin, Jonathan L., MD, Hacke, Werner, MD, Singer, Daniel E., MD, Hankey, Graeme J., MD, Breithardt, Gunter, MD, Fox, Keith A.A., MB, ChB, Califf, Robert M., MD

“…Objectives This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with…”
Get full text

Platelet Function Monitoring in Patients With Coronary Artery Disease by Gurbel, Paul A., MD, Becker, Richard C., MD, Mann, Kenneth G., PhD, Steinhubl, Steven R., MD, Michelson, Alan D., MD

“…Platelet Function Monitoring in Patients With Coronary Artery Disease Paul A. Gurbel, Richard C. Becker, Kenneth G. Mann, Steven R. Steinhubl, Alan D…”
Get full text

Effect of genetic variations on ticagrelor plasma levels and clinical outcomes by Varenhorst, Christoph, Eriksson, Niclas, Johansson, Åsa, Barratt, Bryan J, Hagström, Emil, Åkerblom, Axel, Syvänen, Ann-Christine, Becker, Richard C, James, Stefan K, Katus, Hugo A, Husted, Steen, Steg, Ph Gabriel, Siegbahn, Agneta, Voora, Deepak, Teng, Renli, Storey, Robert F, Wallentin, Lars

“…Ticagrelor, a direct-acting P2Y12-receptor antagonist, is rapidly absorbed and partly metabolized to the major metabolite AR-C124910XX (ARC). To identify…”
Get full text

Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial by Kang, Hyun-Jae, MD, PhD, Clare, Robert M., MS, Gao, Runlin, MD, Held, Claes, MD, Himmelmann, Anders, MD, PhD, James, Stefan K., MD, PhD, Lim, Soo Teik, MD, Santoso, Anwar, MD, PhD, Yu, Cheuk-Man, MD, Wallentin, Lars, MD, PhD, Becker, Richard C., MD

“…Background In the PLATO trial, ticagrelor was superior to clopidogrel in reducing cardiovascular events among patients with acute coronary syndrome (ACS) at…”
Get full text

Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial) by Bansilal, Sameer, MD, Bloomgarden, Zachary, MD, Halperin, Jonathan L., MD, Hellkamp, Anne S., MS, Lokhnygina, Yuliya, PhD, Patel, Manesh R., MD, Becker, Richard C., MD, Breithardt, Günter, MD, Hacke, Werner, MD, Hankey, Graeme J., MD, Nessel, Christopher C., MD, Singer, Daniel E., MD, Berkowitz, Scott D., MD, Piccini, Jonathan P., MD, Mahaffey, Kenneth W., MD, Fox, Keith A.A., MB, ChB

“…Background The prevalence of both atrial fibrillation (AF) and diabetes mellitus (DM) are rising, and these conditions often occur together. Also, DM is an…”
Get full text

Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial by Lincoff, A Michael, Prof, Mehran, Roxana, Prof, Povsic, Thomas J, MD, Zelenkofske, Steven L, DO, Huang, Zhen, MS, Armstrong, Paul W, Prof, Steg, P Gabriel, Prof, Bode, Christoph, Prof, Cohen, Mauricio G, MD, Buller, Christopher, Prof, Laanmets, Peep, MD, Valgimigli, Marco, MD, Marandi, Toomas, MD, Fridrich, Viliam, MD, Cantor, Warren J, MD, Merkely, Bela, Prof, Lopez-Sendon, Jose, Prof, Cornel, Jan H, MD, Kasprzak, Jaroslaw D, Prof, Aschermann, Michael, Prof, Guetta, Victor, Prof, Morais, Joao, MD, Sinnaeve, Peter R, Prof, Huber, Kurt, Prof, Stables, Rod, DM, Sellers, Mary Ann, MSN, Borgman, Marilyn, BSN, Glenn, Lauren, MS, Levinson, Arnold I, Prof, Lopes, Renato D, MD, Hasselblad, Vic, Prof, Becker, Richard C, Prof, Alexander, John H, Prof

“…Summary Background REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a…”
Get full text

Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians by Mehta, Radha, Athar, Muhammad, Girgis, Sameh, Hassan, Atif, Becker, Richard C.

“…Von Willebrand Factor (vWF) is a large glycoprotein with a broad range of physiological and pathological functions in health and disease. While vWF is critical…”
Get full text